Bookmark and Share
Biobusiness Network
01 July, 2011
Download Brochure
   
   
   
   
   
 
 
Email Updates
 
   
   
   
   
   
 

Download updated agenda here

Main Conference Day Two

September, 30th 2010

8.15 Registration and Coffee
Registration and Coffee
8.45 Chairman's welcome
Chairman's welcome
9:00 Case Study: The Acquisition Of Novexel By AstraZeneca
Case Study: The Acquisition Of Novexel By AstraZeneca
Iain Buchanan, CEO, Novexel
Karen Gallant, Business Development Director, Infection in Strategic Partnering and Business Development, AstraZeneca
  • Context of the anti-infective market and the need for novel approaches
  • Company profi le in anti-infectives: Novexel and AstraZeneca
  • Assessing the strategic rationale for M&A and the structure of the transaction
  • The outcome: success factors and lessons learned
11230_004_speaker_Iain_Buchanan

Iain Buchanan
CEO, Novexel
11230_004_speaker_Karen_Gallant

Karen Gallant
Business Development Director, Infection in Strategic Partnering and Business Development, AstraZeneca
9:30 Panel Discussion - BioPharma Focus: What Can Big Pharma Learn From The Biotech World?:
Panel Discussion - BioPharma Focus: What Can Big Pharma Learn From The Biotech World?:
Roland Kozlowski, CEO, Lectus Therapeutics
Kim Koh Bill, Vice-President, Corporate Development, Debiopharm S.A
Paula Zeilon, CEO, Alligator BioScience
Kees Lucas, MD, Middenduin Life Sciences
  • Balancing the innovation and entrepreneurship of biotechs with the structure and organisation of big pharma
  • Advantages of being big (fi nancial strength and organisation resilience) versus the inhibitors (bureaucracy and infl exibility)
  • Can you be big and small at once?
  • Bridging the communication gap between pharma and biotech companies
  • How can deal-making be improved if pharma learn a lesson or two from their biotech partners?
speaker_default

Roland Kozlowski
CEO, Lectus Therapeutics
11230_004_speaker_Kim_Koh_Bill

Kim Koh Bill
Vice-President, Corporate Development, Debiopharm S.A
11230_004_speaker_Paula_Zeilon

Paula Zeilon
CEO, Alligator BioScience

Paula Zeilon has more than 20 years of experience from the life science industry, from a broad range of functions; international sales & marketing, business development, general management and product development. She is acting CEO of Alligator Bioscience AB and partner of Conlega Biobusiness Development and Management. Paula Zeilon holds a master of science degree in Chemical Engi [read more]
speaker_default

Kees Lucas
MD, Middenduin Life Sciences
10:00 Case Study: Merck & Co. Entering The German Chemical Case Study: Merck & Co. Entering The German Chemical
Case Study: Merck & Co. Entering The German Chemical Case Study: Merck & Co. Entering The German Chemical
Dr Manfred Horst, Director Scientific Liaison France and Germany, Merck&Co

11230_004_speaker_Dr_Manfred_Horst

Dr Manfred Horst
Director Scientific Liaison France and Germany, Merck&Co
10:30 Panel Discussion: The Emergence And Growth Of Corporate VCs – Understanding The Issues And Evaluating The Players
Panel Discussion: The Emergence And Growth Of Corporate VCs – Understanding The Issues And Evaluating The Players
Graziano Seghezzi, Partner, Sofinnova Partners
Roel Bulthuis, Head, Merck Serono Ventures
  • The increasing prominence of big pharma in funding early-stage drug discovery and development: strategic objectives and compensation structures
  • Avoiding the risks associated with long-term partnerships and licensing deals
  • Outlining the challenges and opportunities for biotechs: from funding to investment policies
  • Does the growth in CVCs inhibit future partnering prospects or will they rise to the challenge?
  • Assessing the pros and cons from the perspective of biotechs
11230_004_speaker_Graziano_Seghezzi

Graziano Seghezzi
Partner, Sofinnova Partners

Graziano Seghezzi brings nearly a decade of European venture capital investment experience to Sofinnova Partners, where he has been a partner focused on life sciences investment since joining the firm in 2006.

Graziano has been instrumental in targeting, investing in, and nurturing the growth of a number of Sofinnova Partners’ portfolio [read more]

11230_004_speaker_roel_bulthuis

Roel Bulthuis
Head, Merck Serono Ventures
Morning Coffee
No session description available.
11:30 Panel Discussion: Is the Partnering Paradigm Alive And Well?
Panel Discussion: Is the Partnering Paradigm Alive And Well?
Gary Deeb, VP of Global Licensing & Business Development, Glenmark Pharmaceuticals
Jeremy Carmichael, Head fo Business Development, Astex, and leading representative, GSK,
Magnus Bjorsne, Business Development Director, AstraZeneca
Katherine Cohen, Global Head of Corporate & Business Development , Intercell
  • Is the age of doing a deal and retaining partnering over in the pursuit for fast bucks?
  • Is partnering the sole customer or is there the game of building new companies?
  • What does the future look like for partnering and how do you need to adapt?
11230_004_speaker_Gary_Deeb

Gary Deeb
VP of Global Licensing & Business Development, Glenmark Pharmaceuticals
11230_004_speaker_Jeremy_Carmichael

Jeremy Carmichael
Head fo Business Development, Astex, and leading representative, GSK,

speaker_default

Magnus Bjorsne
Business Development Director, AstraZeneca
11230_004_speaker_Katherine_Cohen

Katherine Cohen
Global Head of Corporate & Business Development , Intercell

 Dr. Katherine Cohen has over 18 years of leadership experience in the biotech and pharmaceutical industry and has worked across three continents in Europe, U.S., and China. She is a member of the Management Committee, Senior Vice President and Global Head of Corporate & Business Development at Intercell and is responsible for global business development, M&A [read more]
12:00 Panel Discussion: Exploring New And Alternative Models To Enhance Future R&D Collaboration
  • Which R&D developments and innovative new treatments will expand the pharma biotech market
  • Key ways to cost-eff ectively and innovatively increase R&D capabilities and secure new R&D partnerships
  • Who is responsible for driving R&D collaboration and how are such partnerships structured?
  • Evaluating the latest technologies to drive R&D innovation and ensure long term industry sustainment
  • Solving the pre-clinical translation problem
13.00 Networking Lunch
Networking Lunch
15.45 Afternoon Tea
Afternoon Tea
Theme1 Master No FeaturePanel PageName:agenda.aspx